Diabetes Therapies & Diagnositcs

Global Market for Diabetes Therapies & Diagnostics to be Worth $51.2 billion in 2015

The diabetes market, consisting mainly of Type 1 and Type 2 diabetes, is large and growing significantly.

 

According to a new technical market research report, 'Diabetes Therapies and Diagnostics' from BCC Research, the global market value for diabetes therapies and diagnostics is an estimated $38 billion in 2010, but is expected to increase to $51.2 billion in 2015, for a 5-year compound annual growth rate (CAGR) of 6.1 per cent.

 

 

The largest segment of the market, insulin products (including administration devices), is estimated to be worth $16.4 billion in 2010, and is expected to increase at a CAGR of 6.1 per cent to reach $22 billion in 2015.

Monitoring devices and accessories, the second-largest segment, is expected to reach $14.1 billion in 2015, after increasing from the 2010 estimate of $11.3 billion at a CAGR of 4.5 per cent. The fastest-growing segment, oral hypoglycemic drugs, is projected to increase at a CAGR of 8 per cent, increasing from an estimated $10.3 billion in 2010 to $15.1 billion in 2015.

The diabetes market, consisting mainly of Type 1 and Type 2 diabetes, is large and growing significantly. Type 1 diabetes is an autoimmune disease; it appears in childhood, is lifelong and currently must be treated with insulin. Type 2 diabetes typically appears in middle age. It is linked to obesity and therefore is more prevalent in developed countries with relatively affluent lifestyles, sedentary occupations and dietary overindulgence. Monitoring devices include blood glucose monitors and various types of accessories such as lancing devices used to draw the droplets of blood required for glucose measurement.

It is widely recognised that the prevalence of the commonest type of diabetes mellitus, type 2, is now reaching epidemic proportions all over the world. Cases of type 1 DM are also on the increase, although to a less spectacular degree.

This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, both in global terms and analysed by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for main drug and device categories, and breakdowns are provided for several national markets.

This report is designed to satisfy the information needs of a wide variety of individuals involved in the diabetes marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends.